June 18, 2020: CCX Media visited Francis Medical for exclusive interviews with CEO and President, Mike Kujak, and Founder and CTO, Michael Hoey. Their two-minute video includes an explanation of our revolutionary water vapor therapy, as well as plans for the future, including our VAPOR 1 clinical study
June 9, 2020: Francis Medical, Inc. announces the enrollment of their first patient in the company’s VAPOR 1 clinical study, an early feasibility study evaluating the safety and efficacy of the company’s minimally invasive water vapor ablation therapy for the treatment of prostate cancer
December 17, 2018: Francis Medical, Inc. has been featured in BioWorld MedTech, a leading news source of advances in medical technology
The Vanquish® Water Vapor Ablation System has been cleared as a tool for the thermal ablation of targeted prostate tissue via a transurethral approach. The FDA has not evaluated the Vanquish System for the treatment of any disease, including prostate cancer, or evaluated the Vanquish System for any long-term prostate cancer treatment outcomes.
Federal law (USA) restricts this device to sale by or on the order of a physician.
Refer to the device User Manual for a list of contraindications, warnings, and cautions.
Training: Do not operate the Vanquish System without completing Francis Medical-provided physician training. Untrained operation of the device may lead to improper use. Improper use can result in patient injury or equipment malfunction.